Dr. Markus Haeberlein spent 15 years at AstraZeneca in positions of increasing responsibility, most recently as Global Chemistry Network leader which covered all chemistry departments globally in Discovery and Development (+1000 chemist). As Executive Director and Head of Medicinal Chemistry, CNS and Pain IMed, he directly oversaw more than 100 internal scientists as well as all outsourced activities. Dr. Haeberlein has an extensive knowledge in neuroscience drug discovery and contributed to more than 17 neurology and pain drug candidates as well as novel PET ligands. In 2004 he received the AstraZeneca Global Science and Technology Award for his scientific contributions. He received a PhD in physical chemistry, computational chemistry and an MSc in physical chemistry, biochemistry, organic, chemistry from KTH, Royal Institute of Technology in Stockholm, Sweden.